NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Public ClinicalTrials.gov record NCT00856375. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naive, KRAS-Mutant, Metastatic Colorectal Cancer (mCRC)
Study identification
- NCT ID
- NCT00856375
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Nektar Therapeutics
- Industry
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- NKTR-102 Drug
- irinotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2008
- Primary completion
- Jun 30, 2014
- Completion
- Nov 30, 2014
- Last update posted
- Jul 11, 2021
2008 – 2014
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site - Peoria | Peoria | Arizona | 85381 | — |
| Investigator Site - Burbank | Burbank | California | 91505 | — |
| Investigator Site - Los Angeles | Los Angeles | California | 90033 | — |
| Investigator Site - Vallejo | Vallejo | California | 94589 | — |
| Investigator Site - Centralia | Centralia | Illinois | 62801 | — |
| Investigator Site - Louisville | Louisville | Kentucky | 40202 | — |
| Investigator Site - Detroit | Detroit | Michigan | 48201 | — |
| Investigator Site - Buffalo | Buffalo | New York | 14215 | — |
| Investigator Site - Knoxville | Knoxville | Tennessee | 37909 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00856375, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00856375 live on ClinicalTrials.gov.